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ABSTRACT
Noha Shalaby, The American University in Cairo
Advisor: Dr. Khalil ElKhodary, The American University in Cairo
Co-advisor: Dr. Nejib Zemzemi, Carmen Group, INRIA, France
Computational Modeling of Nanodrug-induced effect on Cardiac Electromechanics
This work generally aims to promote the use of computational models for predicting
side effects of nanodrugs under development, as a means to speed up the cycle of drug
development, with potential savings on testing, and reduction in the need for animal
or human testing.
The specific objective of this thesis has been to accurately model a single ventricular
contraction-relaxation cycle, and monitor the effects induced by nanodrugs on the
electro-mechano-physiology of the left and right ventricles.
Nanodrug interaction with ion channels located on cardiac cell membranes, such as
those for sodium, potassium and calcium, can distort an electrical wave propagating
through the tissue and can affect cardiac macroscale functions. In this study, a
material model after Holzapfel and Ogden was developed to account for the
anisotropic hyperelastic behavior of cardiac tissue, which was implemented on the
open source software library Chaste. A coupled drug-electro-mechano-physiological
system was then set up, also on Chaste, where a nanodrug effect was introduced into
the cellular structure (nanoscale) as an ion channel inhibitor, and its influence then
solved for, with respect to resulting electro-mechanical ventricular behaviors. Using
quantifiable biomarkers, these effects were compared to the literature and clinical
data.
In this work we identified the following main results. Nanodrugs causing sodium
channel blockage were found to produce the anticipated delays in electro-mechanics.
Our study further predicted additional effects on LV twisting and LV & RV strain. On
the other hand, nanodrugs causing potassium and calcium channel blockage revealed
that cardiac mechanics is less responsive to mild alterations in electrophysiology, than
electrophysiology is to ionic changes. Nonetheless, it is important to quantify these
changes, as even a very small deviation from normal could accumulate over multiple
cardiac cycles, and lead to adverse consequences on cardiac health in the long term.
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1) Introduction
The objective of this study is to model a single ventricular contractionrelaxation cycle and monitor the nanodrug-induced effect on their electro-mechanophysiology. The introduction is divided into subsections. First, the structure and
function of the heart will be briefly stated to clarify the terminology that will be used
throughout the thesis. Next, nanomedicine is introduced and how its use can affect the
heart's functionality. After that, the motivation for testing nanoparticles for
cardiotoxicity is justified by pointing to a number of studies that have thus far shown
how certain nanoparticles under investigation for nanomedical research can cause
unwanted biological interactions. The following section goes through how
cardiotoxicity is quantified. Following that is a review of how research has been
gauging the risk of drugs being cardiotoxic and the evolution into computational
models for predicitive assessment. Next, the objectives of this thesis are stated in
more detail and the software package chosen to build the problem is presented.
Finally, there is a quick run through the organization of the thesis sections.

A) The Structure and Function of the Heart
The heart is a muscular
electromechanical

organ

that

pumps blood through the body.
It consists of four chambers; two
atria that act as reservoirs for
two

ventricles.

The

endocardium is the innermost
lining of the chambers, the outer
layer of the cardiac muscle is
the

epicardium

with

the Figure 1: A schematic of the heart's structure.
Red arrows indicate oxygenated blood and blue
myocardium cardiac tissue in
arrows indicate deoxygenated blood
between. The whole organ is
covered with a layer called pericardium.1
A cluster of cells located above the right atrium, between the myocardium and
the epicardium, called the sinoatrial (SA) node, acts as the heart's pacemaker,
1

producing regular electrical signals. The signal travels down the atria causing their
contraction and depolarizes the atrioventricular (AV) node, which is another cell
cluster in the center of the heart, between the atria and the ventricles. The electrical
signal activated in the AV node travels down the wall of muscle between the right and
left ventricles, known as the septum, through a bundle of fibers. At the apex of the
heart, which is the very bottom of the heart, the bundle splits into left and right bundle
branches that depolarize the left and right cardiac ventricles from the bottom-up, and
cause their contraction1, as indicated in the schematics of Figure 1.
At the start of a cardiac cycle, the ventricular chambers are in their relaxed
phase, known as ventricular diastole. Blood low in oxygen, collected from the body,
pours from the right atrium into the right ventricle. The ventricular contraction phase
(systole) pumps blood from the right ventricle through the lungs, to obtain oxygen and
to release carbon dioxide. Oxygenated blood returns to the left atrium and passes to
the left ventricle (LV) in ventricular diastole. During systole, the oxygenated blood is
pumped through the circulatory system to the rest of the body to circulate oxygen,
nutrients, and hormones, and to collect waste. Blood flow direction is regulated by
valves.1
Cardiac muscle cells are among a class known as excitable cells, i.e. they
actively respond to an electrical stimulus that initiates the heartbeat, and causing the
flow of ions. Specifically, sodium (Na+), potassium (K+) and calcium (Ca2+) ions flow
via cardiac cell trans-membrane ion channels.2 In a resting heart, the difference in ion
concentrations between the interior and exterior of the cardiac cell maintains a
negative trans-membrane potential.3 Chemicals or drugs interacting with these
channels could cause partial or full ion flow inhibition, thus disturbing the
electrophysiology and mechanical function of the heart.3

B) Nanomedicine and the Heart
Nanoparticles, which are nanomaterials of less than 100 nm in at least one
dimension, are currently a very interesting area of scientific research. With their small
size comes a multitude of highly desirable mechanical, optical, electrical and
chemical properties, lending them well to being used in a variety of fields, including
the biomedical field.4 In particular, nanoparticles have great potential in
2

nanomedicine, which can be defined as the diagnosis, treatment or prevention of
diseases using nanoscale tools, such as sensors, imaging agents, drug delivery systems
or the drug product itself.5 Of special interest is the use of nanoparticles as a drug
delivery system (i.e. nanocarriers) to offer enhanced targeting of diseased tissues,
increased permeability into diseased cells and controlled drug release.6 However,
nanoparticles at times become a likely cause for unwanted toxicological reactions.4
Their high surface area to volume ratio increases their reactivity, which can cause
undesired biological interactions, while their small size allows them to cross
biological barriers with ease, risking their translocation to unplanned targets, e.g the
heart.7
In fact, one of the foremost reasons for drug discontinuation at all phases of
development is cardiotoxicity, in both cardiac and non-cardiac pharmaceuticals.8
Cardiotoxicity can be defined as the occurrence of an electrophysiological
dysfunction of the heart or a mechanical abnormality of cardiac muscular behavior as
a result of the intake of a toxic matter.9 Cardiovascular safety concerns have been
responsible for almost 19% of drug withdrawals in the United States alone, over the
past 40 years, and for 9% of worldwide withdrawals.8
Drug development and approval takes extensive time, money and effort, and is
subject to high failure rates.8 In fact, many promising drugs pass the initial
cytotoxicity (toxic to regular cells) screening only to turn out to be highly cardiotoxic
in preclinical trials.10 Often, adverse drug effects on cardiac function appear only after
completion of clinical trials, or after drug release in the market.11 Detecting adverse
drug interactions at such a late stage could undoubtedly cause a negative impact on a
patient's health and general consumer confidence. Thus, there is increasing interest to
better understand drug-induced cardiovascular complications, and to predict
undesirable side effects at as early a stage in the drug development process as
possible.

C) Nanoparticles Can Cause Cardiotoxicity
Various nanoparticles, used as nanocarriers, have been associated in the
literature with cardiotoxicity. The most commonly used materials for inorganic
nanoparticles are metals and their compounds,6 where gold nanoparticles (AuNPs) are
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one of the most extensively researched.12 Their easy fabrication, tunable size and
shape, and ready functionalization endow them with unique physical, chemical and
optical properties that render them attractive candidates for many diagnostic and
theraputic applications13. Such applications include their use as nanocarriers for
target-specific delivery, and controlled and sustained release of drug molecules14 .
AuNPs are particularly attractive in cancer research,15 especially ultrasmall AuNPs, as
they are able to access cancer cell nuclei causing more damage.16 Problems of toxicity
appear according to the size of the AuNPs and their applied functional groups.7
Several studies in the literature have identified that triphenylphosphine monosulfonate
capped ultrasmall AuNPs of 1.4 nm diameters (Au1.4MS) are highly cardiotoxic, due
to the irreversible binding and blockage of K+ channels.7,10,17
Similarly, silver nanoparticles (AgNPs) also play a part in nanomedicine, in
areas such as biosensing and wound dressing, for their antibacterial properties.
Increasing concentration of AgNPs was tested for its effect on excitable cells, and
concentrations of 10-5 g/ml or higher were shown to have an inhibitory effect on the
Na+ channel altering cellular electrophysiology.18 Quantum Dots are another widely
researched material on the nanoscale that exhibit excellent imaging and cell tracking
properties, but have a negative effect on the Na+ and Ca2+ channel functionality.19 It
has also been found that yttrium released from the growth catalyst of carbon nanotube
has an inhibitory effect on Ca2+ channels.20
On the other hand, oxide nanoparticles are widely used in production leaving
the end user of the product subject to accidental exposure to the nanoparticles
through, for example, inhalation or skin contact.21 Certain oxide nanoparticles have
also been associated with cytotoxicity. Copper Oxide (CuO) nanoparticles have had
their biological effects tested, where they were found to influence the K+ current in
cells, and in turn induce cell inactivation.22 In a later study, CuO nanoparticles were
found to also affect cellular Na+ concentrations, due to their inhibitory effect on the
Na+ channels.23 Furthermore, zinc oxide (ZnO) nanoparticles, have shown great
potential for many applications, including electrical, environmental and, more
recently, biosensing24. However, a concentration of 10-4 g/ml or more has been shown
to activate Na+ channels, thus affecting intracellular ion concentrations and cell
excitability.25 ZnO nanoparticles have also been found to have an inhibitory effect on
Ca2+ entry into the cell.21
4

D) Typical Quantifiers of Cardiotoxicity
We note that most of nanomaterials have been tested for their effect on
excitable neural cells, but not yet for their effect on excitable cardiac cells, which this
study aims to do.
For

an

electrophysiological assessment
of risk from new drugs, in
general, the most commonly
used biomarkers are based on
electrocardiogram
measurements,

(ECG)

especially the

QT interval shown in Figure 2.
ECG refers to electrode readings

Figure 2: Pseudo ECG of normal heart

over time of the electrical activity of the heart, measured off the body surface. The QT
interval is then the time interval between ventricular excitation (Q-wave) and end of
repolarization (T-wave). The QT interval should be less than or equal to 400 ms for an
average heart rate of 72 beats per minute.26
Drugs that prolong or shift the QT interval are considered especially risky and
their development is generally discontinued.27 This is because QT interval alteration
induces disturbances in ventricular contraction patterns and blood Ejection Fractions
(EF), both which compromise heart function. Ventricular strain and EF are thus the
commonly observed biomarkers for drug development and identification of
cardiotoxicity.28

E) Assessing the Risk of (Nano-) Drug Cardiotoxicity
Many experimental studies have been carried out to investigate cardiotoxicity
induced from ion channel blockage. Preclinical studies of drug candidates have
evolved over the years to include in-vitro assessment of their electrophysiological
effect on cardiomyocytes, using a voltage-clamp or patch-clamp technique, which is a
lab technique that measures electric current of single or multiple cell membrane ion
channels.10,29,30 Animal test subjects have also been used for in-vivo assessment of
blood pressure, heart rate and ECG.11,31 However, it has been determined that ion
5

channel currents in cardiomyocytes and their response to drugs is species-specific, and
that even subtle changes in the elctrophysiological response to drugs between human
and nonhuman cells can lead to different organ behaviors, due to the nonlinearity of
the systems.32
To minimize potential risks from cardiotoxicity, much research has focused of
recent on cardiac modeling and simulation, which are becoming an increasingly
popular alternative to clinical and experimental (in-vitro) studies on the human heart.
Modeling and simulation, or in-silico testing, promise a new predictive capability of
biomarkers, for the rigorous evaluation of cardiotoxicity. In-silico methods are
especially sought for, due to their greater safety and their ability to shed light on basic
phenomena, which arise from the chemistry, biology, electrophysiology and
mechanics of the heart, as well as their prediction of the overall behavior of the heart
resulting from the multiscale and multiphysics interactions between such basic
phenomena.33 The Food and Drug Administration (FDA) listed the need for the
development of mathematical and computational models as risk-benefit predictive
tools for nanomedicine research.34 Such models can however only be valuable, when
their predictions compare closely to clinical data and biomarkers.

F) Computational Methods for Predictive Assessment
Toward achieving such close comparison between in-vivo and in-silico, a
number of human action potential models have been put forward in the literature,
each aiming to accurately describe the cycle of depolarization and repolarization of
single human cardiac cells. Common to these models is that they lay coupled systems
of ordinary differential equations (ODEs), for a description of ionic channels,
exchangers and pumps, which collectively cause an action potential and regulate
cellular sodium, potassium and calcium concentrations and fluxes.35–37
Such single cell models alone have been found inadequate for the prediction of
clinically accurate ECG measurements. This is because single cell models necessarily
ignore cardiac muscle fiber (myofiber) orientation, and surrounding tissue
conductance, in generating and controlling the action potential. Multi-cell models
have thus been developed, which combine single cell models as one, two or three
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dimensional fibers and sheets, so as to better simulate the effect of single or multiple
ion channel blocks.38,39
More recently, advanced models have been introduced to relate drug effects on
cardiac electro-physiology. For instance, the Cardiac Safety Simulator (CSS) is a
commercial tool, made available from Certara, developed for the testing of ion
channel activity, with population variability which adds the likely impact of age,
ethnicity and gender. It has been found to be able to predict the average effect of drugs
on ECG and QT change. However, insufficient studies have been carried out using
this tool to accurately confirm its predictive performance.28,40,41 Nonetheless, evidence
suggests cardiac electro-physiological models are rapidly advancing, having evolved
from single cell predictions, to large scale models embedded in the torso, or even
whole body geometries with body surface potentials, where single and multiple
channel blocks can be recorded, analyzed and compared.26,42–44
Very recently, these sophisticated electro-physiological models have been
integrated with cardiac mechanics simulators, in a multiphysics computational
framework. This effort has been motivated by a need to investigate drug-induced
changes to cardiac muscle intractability, which can have dangerous repercussions for
patients. These changes are particularly difficult to measure clinically, making insilico testing especially relevant. A few studies have been published, aiming to capture
the multiscale interactions that characterize human cardiac electromechanics, from the
drug and cell levels to the organ level.33,45 Some studies are now focused on building
a model for the complex fiber orientation of the cardiac walls, in order to properly
capture that rotation and twist of the LV, and use the quantification and interpretation
of LV torsion as a potential clinical tool.46,47 In fact, LV twist is an important
phenomenon that plays a significant role in blood ejection, and has, until recently,
been somewhat neglected in the field of cardiac mechanics.48 Fewer models have
been built for both right and left ventricles.49–51 Other models aim to develop the most
accurate material law describing the material properties of cardiac tissue, both active
and passive (with respect to electrical excitation), and to accurately predict
corresponding stresses, strains and volume change from cardiac contraction.52,53
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The largest ongoing cardiac electromechanical modeling project is the Living
Heart Project1. It is a whole heart model developed by Simulia, through a consortium
of researchers, clinicians and international industries, to create a unified foundation of
cardiac electromechanical modeling and simulation. Their successful combination of
accurate heart geometry and material properties in a multiscale/multiphysics
framework is beginning to produce rather realistic predictions in normal and abnormal
cardiac behavior.50,51 This project, however, has not yet included drug interaction
effects in their electrophysiological models.
In a parallel vein, the challenge of constructing patient-specific geometric
models of the heart, capturing any abnormalities in form, from medical images and
clinical data, is also receiving much research attention.54,55 This effort aims to
improve diagnosis of cardiac diseases, understand the variation of disease across
patients, and predict patient-specific response to alternative interventions and medical
treatments.
Such advances in electromechanical modeling are thus increasingly becoming
an asset to the field of cardiac surgery, by reproducing the effects of heart diseases,
simulating surgeries, predicting stress and strain, and quantifying changes in tissue
material parameters.56 Nevertheless, linking these state-of-the-art electromechanical
methods, mostly available as research codes in testing, to drugs and the assessment of
drug-safety has not taken root yet.28 This points to a fertile ground for a computational
multiphysics exploration, to lend its reliable hand to the safe advancement of
nanomedicine.

G) Objectives of this Thesis
It is the objective of this work to link a detailed account of cardiac myofiber
mechanics to drug-induced electro-mechano-physiology. Specifically, this study aims
to setup a computational model of the human ventricles, which integrates nanoscale
ionic flow from myocytic currents, exhibits the chemical interference of drugs and
nano-drug carriers, captures resulting macroscale electrical propagation across
ventricular tissue and resulting tissue contractile behavior, and accurately predicts
associated electrical and mechanical biomarkers. In order to do so, a material law that

1

http://www.3ds.com/products-services/simulia/solutions/life-sciences/the-living-heart-project
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governs orientation-dependent tissue deformation is developed, based on the
Holzapfel and Ogden53 model, and is programmed in this study on the open source
software package Chaste.

H) Why Chaste?
Chaste2 (Cancer, Heart and Soft Tissue Environment) is a C++, object oriented
library developed by the Computational Biology Group in the Department of
Computer Science at the University of Oxford. It incorporates a broad set of
numerical solvers and state-of-the-art algorithms for the service of biological
modeling.57,58 Its ionic and reaction-diffusion models have been verified and
extensively used for cardiac electrophysiological modeling.26,38,39,42,44,59 As it is an
opensource software, its components are in a constant state of development.
The selected material law we developed on Chaste describes hyperelastic
tissue properties that incorporate myofiber and sheet directions in the passive stress
tensor. The material model is herein extended to implicit time integration by
formulating an appropriate Jacobian (fourth-rank elasticity tensor). Coupling between
the ionic, electrophysiological and mechanical models is then implemented on
Chaste’s multiphysics solver, as discussed in57,60, to unveil new insights into the
influence of drugs on the heart, ultimately advancing the field of computational
nanomedicine.

I) Organization of the Thesis
This thesis is organized as follows. In section 2, we go through the
methodology starting with the electrophysiological models in Chaste that are used in
the simulations describing the electrical activity in a single cardiac cell and in the
whole organ. After that we move on to the mechanical response discussing the fiber
orientation in more detail as well as the active contraction model and passive material
models of the mechanical behavior followed by how the coupling of these different
components is carried out in Chaste. In section 3, the results of the
electrophysiological simulations on an anatomically detailed ventricular mesh and the
results of the coupled models are presented under normal conditions, under the effect
2

http://www.cs.ox.ac.uk/chaste/
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of a Na+ channel blocker , under the effect of ultra-small gold nanoparticles on the K+
channel and under the effect of a Ca2+ channel blocker. We conclude by summarizing
our current findings and discussing potential future research directions in section 4.
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2) Methodology
A) Electrophysiology
The flux of ions and associated electrical activity of an individual myocyte are
essential phenomena to be modeled in cardiac electrophysiology; these may in general
be well characterized by the various cell models available in literature.35–37,61,62 Cell
models must then be linked to governing differential equations that are responsible for
the propagation of electrical activity across cardiac tissue.63

i)

Cellular Level Models of Electrical Activity
Embedded protein structures on cell membranes form channels, exchangers

and pumps responsible for the passage of ions in and out of the cell. Each protein
structure is specific to one or two ions, responding to changes in potential across the
cell membrane known as trans-membrane potential. Balancing the flow and
intracellular concentrations of sodium (Na+), potassium (K+) and calcium (Ca2+) ions
is regulated by the opening and closing of these channels, and their generation of an
action potential. The cardiac action potential is the sharp activation and the slow
repolarization of the cardiac cell membrane.63 The normal cycle shown in Figure 3
consists of 5 phases. The rapid depolarization (Phase 0), the early/rapid repolarization
(Phase 1), the plateau (Phase 2), the late repolarization (Phase 3) and the resting phase
(Phase 4).2 In particular, in resting tissue the difference in intracellular and
extracellular ionic concentrations amounts to a negative trans-membrane potential.
Application of a significant electrical stimulus (e.g. incoming from pace-maker cells)
then leads to the depolarization of the trans-membrane potential, by activating the
Na+ channels, which allow Na+ into the cell. A positive trans-membrane potential, on
the other hand, activates the Ca2+ and K+ channels, which pass Ca2+ into the cell and
K+ out of the cell, resulting in a plateauing of the action potential. A rise in
intracellular Ca2+ concentration instigates myocytic contraction, while the fall in
intracellular K+ concentration repolarizes the trans-membrane potential back to its
negative resting value.3
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Figure 3: Normal action potential generated by membrane currents
Corresponding mathematical descriptions of this electrical activity in
myocytes are all based on the work introduced by Hodgkin and Huxley61 in the 1950s,
where they described the trans-membrane potential and the cell membrane
permeability, using just four ODEs. Models incorporating more cell properties and
variables were later developed to increase their accuracy and strengthen their impact.
In general, an ionic model needs to be detailed enough to model the properties of a
single myocyte, but maintain computational efficiency, which is required for large
scale simulations (of the whole heart).63
One of the most extensively used ionic models in literature26,39,41,43,64,65 is the
TenTusscher and Panfilov human action potential model.35,66 It has been verified as an
efficient model with reliable results based on experimental data.36,67 It combines the
15 major ionic channels of the human ventricular cardiac myocyte, which consist of
10 transmembrane channels, 3 intracellular calcium channels, 1 sodium-potassium
exchanger (INaK) and 1 sodium-calcium pump (INaCa) as shown in Figure 4. The cell
membrane ionic currents modeled are the fast Na+ current (INa), the L-type Ca2+
current (IcaL), the background Na+ and Ca2+ leakage currents (IbNa, IbCa), the plateau
Ca2+ and K+ currents (IpCa, IpK), the slow delayed rectifier current (IKs), rapid delayed
rectifier current (IKr), the inward rectifier K+ current (IK1) and the transient outward
current (Ito). Differences in the Iks and the Ito differentiate between epicardial,
endocardial and mid-wall cells giving more accurate electrical conduction
patterns.35,63 The intracellular Ca2+ dynamics, which are a crucial link between the
electrical activity and the cell contraction, are modeled by the leakage current from
12

the sarcoplasmic reticulum (Ileak), the calcium-induced Ca2+ release current (Irel) and
the pump current taking up Ca2+ into the sarcoplasmic reticulum (Iup).35 We will use
the TenTusscher and Panfilov human action potential model66 (TP06) in the
simulations of this study which is a reduced, more efficient version derived from the
original model. The sum of all the trans-membrane ionic currents (Iion) computed from
TP06 will then be passed on to solve the electrophysiological field equation.

Figure 4: Diagram of ion movement across cardiac cell membrane and
sarcoplasmic reticulum as described by the Ten Tusscher and Panfilov model

ii)

Capturing Drug Interaction
There are two basic ways certain drug molecules can cause ionic flow

inhibition by binding to ion channels. The first is when binding occurs near a
channel’s opening, which results in a physical barrier in the path of ionic flow. The
second is a structural change induced in ion channel proteins due to drug binding,
which also leads to ionic flow restriction.3 In both cases a modification may be
imparted to the TP06 action potential to model the inhibitory effect on Na+ and K+
channels of drugs in relation to dosage, half maximal inhibitory concentration (IC 50),
and the Hill coefficient.26 Hill coefficient is a quantification of the affinity of
molecules or ions to bind to an already bound receptor. A value of more or less than
one indicates that molecules or ions bound to a receptor increase or decrease,
respectively, the likelihood of other molecules or ions to bind to that receptor, while
having a Hill coefficient of one means the binding affinity is unaffected by the
receptor's state, bound or unbound.3 In particular, for the TP06 ionic model, the effect
13

of an investigated drug will be accounted for by altering ionic conductances (g) in the
action potential model. The following formula is often used, with Hill coefficient n =
1;42
(2.1)
In equation (2.1) the degree of channel blockage is made dependent on the dosage [D]
and IC50 of the drug. Index j represents the targeted ion channel.26

iii)

Computational Implementation
CellML was used for the implementation of the aforementioned cell model.

CellML is an XML-based language developed to provide a defined form and common
basis for the development of mathematical cell models, with an aim to avoid errors
that might arise in the exchange channel between researchers, during translation from
one programming language to another, or from poor documentation. CellML
facilitates the process of integrating selected cell models with different simulation
environments. In particular, PyCML is a Python CellML tool integrated in Chaste that
generates C++ classes from cardiac cell models linked to the electromechanical solver
in Chaste.68
As the system of ODEs representing the cardiac cell has a 'stiff' nature, due to
the very fast upstroke of the action potential compared to the remaining simulation
activities, a special solver is required.68 CellML does not specify how the system of
ODEs should be solved, leaving the choice to the users. In Chaste, the user could
either code their own solvers or use PyCML to link to the CVODE library provided
by Sundials3 to solve stiff ODE systems.69

iv)

Tissue Level Models for Electrical Excitation and Recovery
Modeling the entire organ (the heart) cell by cell would be too

computationally expensive, so a continuum approach is usually adopted to conduct
simulations on this physiological scale. The idea is to avoid modeling the cellular
scale explicitly by instead studying volume averaged quantities for cells, which are
small enough compared to the overall heart domain, and may thus be treated as points
in a continuum.63 The corresponding continuum field equations which need to be
3

https://computation.llnl.gov/casc/sundials/main.html
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solved (numerically integrated) to simulate electrical excitation and recovery across
ventricular tissue go by the name the bidomain model.70
The bidomain model was developed in the 1970s71 and set the benchmark for
studying electrophysiology of the heart. It divides the ventricular system into
intracellular and extracellular domains. Cardiac cells are then assumed to be
electrically connected to allow an electric stimulus to propagate throughout the heart
via a gap-junction mechanism.63
We note that cardiac tissue is microstructured, so that corresponding electrical
properties are in general anisotropic. The microstructure of ventricular tissue is
discussed later in fuller detail. Nonetheless, we here must recognize that cardiac tissue
is in fact organized in lateral sheets of fibers, and that tissue conductivity is higher
when stimulated parallel to the alignment of its myocytes than when perpendicular. As
such, at each given point three distinct values for conductivity are assumed; along the
fibers (σf), along the sheets but perpendicular to the fibers (σs), and perpendicular to
both the fiber and sheet directions (σn). This assumption gives rise to two diagonal
conductivity tensors, one for intracellular conductance (Di) and one for extracellular
conductance (De), of the form:63,70

(2.2)

The bidomain model can be significantly simplified into the monodomain
model by addressing the trans-membrane potential on the whole, and assuming
anisotropy between intracellular and extracellular conductances are related by the
equation σe = λσi, where λ is a scalar constant. An effective conductivity for the
monodomain equation thus substitutes the two conductivities of the bidomain
equation as follows:
(2.3)
Furthermore, extracellular applied current Ieapplied from the bidomain equation
also changes in the monodomain equation to70:
(2.4)
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For the simulations herein, the monodomain equation was selected to provide
the electrical image of cardiac tissue over a cardiac cycle. It is less computationally
demanding than the bidomain model, and gives sufficiently accurate results with
respect to electrical propagation and ionic channel blocking72. It is thus also assumed
adequate to drive the associated cardiac mechanical cycle, which is the focus of the
modeling effort developed in this work. The governing monodomain equation can be
expressed as:
(2.5)
where χ is the surface-area-to-volume ratio, Vm is the trans-membrane voltage, t is the
time, Cm is the capacitance across the membrane, DM is the effective conductance
tensor, Iapplied is the applied stimulus and Iion is the value passed on from the TP06
ionic model, representing sum of all the trans-membrane ionic currents.73

v)

Computational Implementation
As a parabolic partial differential equation (PDE), equation (2.5) requires a

simple linear parabolic solver, which is predefined on Chaste. The solver employs the
finite element method (FEM). The weak form of the monodomain equation is obtained
by multiplying it by basis functions (ϕ), one for each node of the cardiac model, such
that these functions satisfy the Neumann boundary condition, which for the case of
the monodomain equation requires that their derivatives on the heart surface be zero,
i.e. that no electrical flux out of the heart would be permitted.74
The discretized form of the problem becomes74 find Vm+1 where;
(2.6)
M is the mass matrix and K is the conductance dependent stiffness matrix given by;
σ

(2.7)

Fm is a vector of body current and stimuli for each node, and csurf is a vector of
surface stimuli for each node, which in this case is set to zero. These vectors are
defined as follows:
(2.8)
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vi)

Cell-level and Tissue-level Model Coupling
Once an external stimulus is

applied

to

the

cardiac

tissue,

the

corresponding change in trans-membrane
potential is communicated to the ionic
model to solve for the associated ionic
flow through the myocyte channels,
pumps and exchangers. In the subsequent

Figure 5: Excitation/Recovery model
timesteps there is a back and forth and ionic model coupling
relationship between the two models, as shown in Figure 5. The current (Iion)
calculated by the ionic model is fed to the monodomain reaction-diffusion equation,
and the voltage and calcium concentration are updated as state variables which affect
the

ionic

concentrations

and

current
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flow

on

the

cellular

level.

B) Tissue Mechanics
i)

Ventricular Fiber Structure & Relevance to Tissue
Mechanics
Modeling living soft tissue mechanics is a topic of interest in much ongoing

international research for a variety of reasons. If we confine our vision to cardiac
research, however, a rigorous investigation of tissue mechanics holds promise in the
prediction of ventricular volume changes between cardiac contraction and relaxation,
a monitory of cardiac wall thickness variation, a quantification of ventricular twist
and other related phenomena, all which will enable a deeper understanding of the
different mechanisms that govern healthy and unhealthy heart functions.75
The heart however has a complex structure, composed of a multitude of fibers
laid out along different orientations, which are crucial to defining electrical
propagation76 and mechanical contraction patterns.49 Fiber distribution in general
evolves smoothly from a right-handed helix structure in the sub-endocardium (Figure
6A) to a left-handed helical structure in the sub-epicardium (Figure 6B). The
opposition in fiber direction between the sub-epicardium and the sub-endocardium
compels them to contract in different directions. The larger radius of rotation of the
outer epicardial layer dominates the direction of rotation causing twisting and
shearing in the endocardium fibers where strain energy is thus stored and which, when
released, serves for diastolic recoil.77

Figure 6: Fiber distribution evolve from a right-handed helical structure in the
subendocardium (A) to a left-handed helical structure in the subepicardium (B)
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Models of the ventricles that do not capture fiber direction have been found to
lead to a misdistribution of stresses and strains, a decrease in cardiac energy
efficiency, and an overall compromise in the accuracy of the predicted cardiac
electromechanical phenomena.75,77 Hence, proper myofiber orientation modeling has
been a main focus of this work.

ii)

Myofiber Orientation Modeling
The first to analyze the continuous change of fiber angle through the

ventricular wall and the alterations in the fibers between systole and diastole were
Streeter, et al.78 Their model was built from histological datasets, relating well to the
observed physiology of the ventricles, thus remains to date the most widely used fiber
orientation model in cardiac simulations, in spite of its simple form.79 In this model, a
fiber axis is assigned to each element in the ventricular mesh by means of helix angle,
α, according to the following80;
α = R * sign(1 – 2d) |1 – 2d| n

(2.9)

where d is transmural depth and ranges from 0 to 1 from endocardium to epicardium;
R is maximum absolute value of α depending on heart region (see next paragraph),
such that α ranges between R at the epicardium and –R at the endocardium of a given
region, n modulates the transmural variation of α, e.g. linear (n=1) or cubic (n=3). The
sheet axis is then defined as lying in the perpendicular plane to the fiber axis assigned,
and the normal axis is finally defined as the direction orthogonal to them both.53
Simple heart region models merely differentiate between the left ventricle
(LV) and the right ventricle (RV); while more accurate models could differentiate
between 16 myocardial regions of the LV on one hand, and the apical, mid and basal
regions of the RV on the other.46
In this work we thus employed the Streeter model to generate fiber
orientations in the LV and RV, as indicated in Figure 7, having only distinguished two
heart regions: the LV (Figure 7A, 7B) and RV (Figure 7C, 7D) for simplicity.
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Figure 7: Fiber Orientations generated by the Streeter model. A) LV
endocardium, B) LV epicardium, C) RV endocardium, D) RV epicardium

iii)

The Mechanical Behavior of Myofibers
Modeling living soft tissue mechanics is a topic of interest to help monitor the

change in cardiac wall thickness, myofiber structure and ventricular volume between
contraction and relaxation to enable deeper understanding of the different mechanisms
that govern behavior of healthy and unhealthy hearts.75
Two components are necessary to understand the electromechanical
deformation of myofibers accurately. The first component is due to an active cellular
contraction, i.e. an electrically excited contraction, which is responsible for the
generation of an active tension in the myofibers. The second component, on the other
hand, characterizes a passive myofiber mechanical response60, i.e. one intrinsic to
myofiber protein elasticity.
Under a microscope, a muscle fiber can be seen to be composed of many
myofibrils, each consisting of repeated cylindrical sarcomeres, as summarized in
20

Figure 8A. A sarcomere is
comprised

of

contractile

proteins, bounded by Z-disks
(Figure 8B). In particular, thin
filament

proteins, which are

made up of helically arranged
actin monomers (tropomyosin
and troponin) project from both
sides of Z-disks. Furthermore,
myosin thick filament proteins
are located in the middle of the
sarcomere, connected to Z-disks
via very thin, elastic filaments. In
a contracting muscle fiber, an
interaction between thick filament Figure 8: A) Muscle fibre composed of
repeating myofibrils, B) Cylindrical Sarcomere
myosin and thin filament actin
binding sites leads to a sliding action.81

Figure 9: The total contractile force developed during contraction generated by
the sum of active and passive forces
In particular, no active force is developed, as seen in the plot of the active
force in Figure 9 at (a), when a sarcomere is stretched far enough to eliminate overlap
between filaments (Figure 10a), as no cross bridges can form. Changes to the trans21

membrane potential lead to a release
in Ca2+ ions, which bind to troponin
on the thin filament changing its
structure to expose binding sites and
enable the formation of a cross
bridge between myosin and actin
(Figure 10b). These cross bridges
cause shortening of the muscle fiber
by exerting longitudinal forces that
increasing the overlap between the
thick and thin filaments, and result in
increased active contracting force as
seen at (b) in Figure 9. However, as
the

shortening

progresses,

thin

filaments begin to overlap (Figure Figure 10: Different stages of stretch and
10c, 10d) leading to a decrease in compression of a sarcomere during
contraction
potential binding sites, and result in
decreased active force (Figure 9 at (c) and (d)). When thin filaments hit the Z-disks
they push back against the contractile force (Figure 10e), and net active force
becomes zero (Figure 9 at (e)). Maximum force is thus produced when the sarcomere
is at its intermediate length, while no force results at either extreme of length.54
On the other hand, a passive force is present in the muscle irrespective of
electrical excitation due to the (nonlinear) elasticity of connecting filaments in
myofibers and the collagen connective tissue surrounding each muscle fiber. The
active force generated by the cross bridges is independent of the passive force from
elasticity. Thus the active and passive stresses could be superimposed to get the total
force curve, as shown in Figure 9.54

iv)

Active Stress Model
To capture myofiber mechanical response to electrical excitation at each

material point, a calculation of the active tensile (Cauchy) stress tensor, σa, is needed.
Active stress in general depends on the voltage, the intracellular calcium
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concentration, [Ca2+], fiber stretch state ( ), and sometimes the fiber stretch-rate , in
addition to any potential set of state variables.60
The Kerckhoff model82 is a good example of a widely used active stress model.
It contains no rate dependence, and no state variables, beyond [Ca2+], contributing to
desired model simplicity. It nonetheless adequately connects to cellular chemistry
changes, through ionic flux interaction with [Ca2+]. Due to our interest in nano-drug
effects on cardiac electromechanics in this work, we are thus satisfied with this rather
simple active stress model.
In this model, first a coefficient of the Cauchy active tension (

) is computed,

which depends functionally (say, function f1) on the time elapsed since electrical
depolarization (ta), sarcomere length (ls) and contractile length (lc) as follows82;
(2.10)
where ls0 is the reference sarcomere length and Ea is the stiffness of the elastic
filament. The function f2 describes active stress dependency on contractile length,
while the function f3 describes active stress dependency on electrical activation time
and the sarcomere length. These two functions are listed below:
(2.11)

(2.12)

where T0, a6 and a7 are active material parameters and tmax, td and tr are activation
duration, activation decay time and activation rise time, respectively.
To construct the active stress tensor (

), fiber direction vectors (f), defined in

the current configuration, are introduced as dyadic bases for the coefficient computed
in equation (2.2). This approach permits directional dependence of active stress in the
model. Pulling back to the undeformed configuration, an active second PiolaKirckhoff (PK2) stress tensor (Tactive) can be recovered as follows74,
(2.13)
23

This pullback operation is necessary to satisfy force equilibrium in the finite
element solver on Chaste, which uses a total Lagrangian formulation. In equation
(2.13) above, J is the determinant of the deformation gradient F, and f0 is the fiber
orientation in the initial (reference) configuration.

v)

Passive Stress Model
In this study, we will make the usual assumption that myofibers are

hyperelastic and that their mechanical response is orientation dependent.53,78
Viscoelastic and poroelastic effects are thus ignored, and heart muscle is treated as
incompressible. An isochoric (constant volume) strain energy function may thus be
introduced as follows83;
Wiso = W(u) – p(I3 - 1)

(2.14)

where W(u) is a strain energy density function of displacement u, and describes
mechanical response to both volumetric and isochoric deformation. p is a Lagrange
multiplier, which may be interpreted as a hydrostatic pressure that penalizes volume
change to enforce isochoric deformation.

a) Holzapfel and Ogden constitutive law
The strain energy function developed by Holzapfel and Ogden53 is used in this
study to compute the passive stress. It is an orthogonal components model based on
shear and biaxial tests performed on a cube of passive myocardium tissue. It can
capture the dissimilar responses of a material in the fiber f, sheet s and normal n
directions. The strain energy function W(u) is written as53;

(2.15)
where a, af, as, afs, b, bf, bs and bfs are experimentally fitted parameters, and d = 3 in
3D models. I1, I4 and I8 are invariants of the right Cauchy-Green strain (C = FTF),
where F = F(u) is the deformation gradient depending on displacements u of in the
neighborhood of material point. I1 is the sole isotropic term included in the energy
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density function. I1 = tr(C), with tr the trace operator, is thus considered to
characterize the behavior of the non-muscular, non-collagenous part of the tissue.53
Anisotropy was introduced in equation (2.15) by specifying one or more
directions of reference, labeled i, and defining the I4 invariant in that direction
according to I4,i = vi.C.vi, where vi is a vector pointing in direction i. The exponential
function applied to the fourth invariant in the fiber (I4,f) and sheet directions (I4,s) is a
good reflection of the high stiffening and energy storage behaviors of muscle fibers
and connecting collagen fibers, respectively. The other invariant included in the strain
energy density function is the coupling invariant (I8,fs = f0.C.s0), for a more detailed
reflection of myofiber inter-dependency of orientations.
We here also note that the I2 invariant was deemed unnecessary to include in
equation (2.15) by Holzapfel and Ogden, while the I3 invariant was omitted for
incompressible tissue behavior, since J = 1 and I3 = J2 = 1. The I4 invariant of the
normal direction (I4.n) was further shown to be dependent on I1, I4,f and I4,s, so that its
inclusion was also unnecessary. Finally, only a coupling of the fiber and sheet
directions associated with fiber stretch was included in equation (2.15), as it was
observed that the shear response in the planes containing the normal direction are
relatively low, and rather similar for both the fiber-normal and sheet-normal planes.53
The derivative of the energy function W with respect to C is then taken to
obtain the PK2 stress, T(C, p), yeilding74;
(2.16)
where,

(2.17)
and I is the identity tensor.
When this model is setup for static finite element solvers, the corresponding Jacobian
(iteration matrix) is needed74, and we derive it in this work as follows;
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(2.18)
Where E is the Green-Lagrange strain tensor, and is the strain measure of choice in
Chaste, which employs the total Lagrangian formulation, wherein E is energetically
conjugate to PK2.
This Holzapfel and Ogden can be reduced to a transversly isotropic model by
reducing the parameters to only 4 parameters; a, b, af and bf, which were shown to
still fit data sets on cardiac mechanics very well. Indeed, in this study, these four
material parameters were used (setting all others to zero) based on one of the most
recent studies by Baillargeon et al.51, which showed improved mechanical predictions
on blood ejection fractions, than competing models with all 8 parameters.50,83

b) Pole-Zero constitutive law
Nash and Hunter52 proposed a transversly isotropic material law based on
biaxial tests performed on thin sections of passive myocardium tissue. The strain
energy function is given as follow;

(2.19)

where the k's, a's and b's are the material parameters and the E is the Green-Lagrange
strain tensor (E = (C – I) / 2)) where C is the right Cauchy-Green strain and I is the
identity tensor.
This constitutive model is already developed on Chaste, but it has not been
chosen in this study to examine nanodrug effects as it has been found to give weak
results in terms of ventricular volume change and ejection fraction as shown later on
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in the thesis. Also, unlike the Holzapfel and Ogden model, it is limited to transverse
isotropy and cannot model orthotropy.53 The biggest problem, however, with this
model is the fact that it needs 18 material parameters. Having that many lineary
dependent parameters makes them difficult to identify84 and sensitive to small
changes in the data.53

c) Mooney-Rivlin constitutive law
The Mooney-Rivlin material law was derived from the work of Mooney85 and
Rivlin86 in large elastic deformations in rubber-like isotropic materials. The strain
energy function is given as;
W(u) = c1 (I1 - 3) + c2 (I2 - 3)

(2.20)

where I1 and I2 are the invariants of the right Cauchy-Green strain (C = FTF), where F
= F(u) is the deformation gradient depending on displacements u of in the
neighborhood of material point. I1 = tr(C), with tr the trace operator, I2 = [(tr (C))2 –
tr(C2)]. c1 and c2 are the material parameters.
This material law is already developed on Chaste, but, as shown later, it gives
weaker mechanical behavior compared to clinical data and compared to the other two
constitutive laws investigated in this thesis. Its problem lies in the fact that it assumes
the material behaves identically in all directions and does not take into account the
fiber or sheet directions which is not the behavior of the cardiac tissue.87 Hence, this
material law was not used in this study to investigate the effect of nanodrugs on the
cardiac mechanical deformation.
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C) Electromechanical
i)

Coupling Summary
Multiscale electromechanical modeling (itself multiphysics) is required in this

work, since coupling appears between different length and time scales of our model
ranging from molecular myofilaments (length ≈ 1.5-3.5 µm) to the organ level
(volume ≈ 280 cm3), and from rapid changes in ionic fluxes to the much slower
muscle contraction. In summary, ionic models are first solved at the subcellular level,
then ion concentrations are fed into the reaction-diffusion electrophysiological
equation to study signal propagation across the organ, and into the active stress model
to predict resulting mechanical deformation due to myofilament Ca2+ based
activation. This is followed by passive tissue mechanics solving, which updates the
electrical model with fiber and sheet orientations and the stretch-activated ionic
channels. Clearly then all levels have a direct effect on each other via parameter
passing, as summarized in Figure 11.

Figure 11: Components of the cardiac electromechanical model
However, the feedback of the mechanical deformation on the electrical
conductance was not accounted for in this work since it is very computationally
expensive to apply on big meshes such as the one used here. It would be quite
interesting to see the feedback effect and compare with and without it on a more
optimized tissue mechanics solver. The feedback to the ionic model was also removed
since implementing how the stretch affects the stretch-dependent ion channels is
outside the scope of this work.
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ii)

Stress Model Implementation on Chaste
When solving tissue deformation, at each instant inertial effects are neglected

and the tissue is assumed to be in equilibrium. The weak form of the equilibrium
equations needed to get the deformed configuration in the incompressible case using
the finite element methods are as follows74;

(2.21)
(2.22)
where T = Tactive + Tpassive, V0 is the subspace of deformations and W is the subspace
of pressures,

0

is the density, b is the body force per unit mass and s is the surface

force. Equation (2.22) is the incompressibility constraint. Since gravity is neglected
and there are no applied forces, the last 2 terms of equation (2.21) are zero giving the
equilibrium equations for the incompressible volume the following form:
(2.23)
(2.24)
Mechanical deformation is solved for on a quadratic mesh where quadratic
interpolation is used for solving the displacement over N nodes and linear
interpolation is used for solving the pressure over M nodes making the overall number
of unknowns in the 3D mesh 3N + M.
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3) Results and Discussion
A) Problem Setup
The geometrical model used in this work is derived from CT data of the
human ventricular chambers.76,88 The mesh is confined to the left and right ventricles
only and meshed into 238,382 elements. Since the electrical and mechanical meshes
have different requirements regarding element type and element size, different
computational meshes are used for each. The electric mesh is a linear tetrahedral mesh
composed of 49,658 nodes. On the other hand, the mechanics mesh is a quadratic
mesh with 354,107 nodes, to avoid pressure instabilities.89 Both meshes are generated
using Chaste.
The simulations were run on an AMD Opteron server with 256 GB of memory
on an Ubuntu 14.04 operating system.

Figure 12: Basal view of ventricular model at time 1 ms highlighting the area of
applied stimulus on the endocardium in A) the left ventricle and B) the right
ventricle
Ventricular tissue was stimulated by -10,000 μA for 1 ms in the endocardium.
Figure 12 highlights the locations where the stimulus was applied in the left (A) and
right (B) ventricle endocardia. The monodomain reaction-diffusion equation was then
solved in our simulations for 400 ms, to ensure complete activation and repolarization
of the ventricles. The corresponding PDE solver on Chaste was called with a time step
of 0.05 ms, Electrical conductivity along the fiber direction was set to 1 mS/cm and
0.3 mS/cm along the sheet and normal directions. and a surface area to volume ratio
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was 200. For the cell model, the ordinary differential equation (ODE) time step was
taken as 0.01 ms.
Dirichlet boundary conditions
were prescribed for our mechanics
model, where the nodes at the very
bottom of the left ventricular apex
(marked in yellow on Figure 13) were
fixed in space in all 3 directions, leaving
the remainder of the mesh to deform
freely. As mentioned earlier, Kerckhoff’s
contraction model is used to calculate
the active tension; its solver was called
with a time step of 0.01 ms. Equations of
Figure 13: Dirichlet boundary
equilibrium were then set to solve once conditions. Nodes at ( z < 0.3) marked
yellow are fixed in x, y, and z directions
every 10 ms.
The Streeter fiber class on Chaste was used to generate the fiber, sheet and
normal directions at each element in the mesh (cell-centered). The vectors defining
the fiber and sheet directions are shown in Figure 14 A and B, respectively. This fiber
definition is necessary for both the electrical conduction and mechanical deformation.

Figure 14: Streeter A) fiber and B) sheet direction vectors mapped on the
ventricular mesh
The post processing for this study was performed on Matlab4 and the
visualization of the mesh, its fibers and its electromechanical properties on Paraview5.

4
5

http://www.mathworks.com/products/matlab/
http://www.paraview.org/
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B) Simulation under normal conditions (Control)
i)

Electrophysiology

a) Pseudo-ECG
The ECG is the recording of the cardiac potential off the body surface. Instead
of solving the expensive problem of a coupled heart-torso model, an approximation
can be made, through an averaging of signal propagation and recording it via an
electrode placed at a specified distance from the heart.88 This approximation is called
the pseudo-ECG and a Chaste post processing class57 has been used to calculate it
using the following formula90;
(3.1)
where Φe is the extracellular potential at location (x’, y’, z’), D is the diffusion
coefficient, Vm is the trans-membrane potential and r is the distance of the electrode
from a source point (x, y, z) on the heart surface to the electrode position (x', y', z')
such that;
r = [(x – x')2 + (y – y')2 + (z – z')2]1/2

(3.2)

Figure 15: Basal (A) and side (B) view of the ventricle model with the electrode
position coordinates at (10, 10, 5)
In this study, the diffusion coefficient was set to 1 and the electrode was
placed in the position specified in Figure 15 such that (x', y', z') = (10.0, 10.0, 5.0), a
location comparable to the surface of the torso. The pseudo-ECG computed from the
voltage is plotted in Figure 16 from the beginning of the QRS complex to the end of
the T-wave (QT interval), to assess ventricular activation and repolarization.91 The
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plot shows a good prediction of the QT interval, with a duration of a little over 350
ms, which is well within the expected range.26

Figure 16: Pseudo-ECG plot of QT interval under normal conditions

b) Action Potential
The action potential (AP) generated by the ion flow through the cardiac cell
membranes is recorded at each time step for every node in the mesh. The AP of a
sample node is plotted in Figure 17 and it shows it undergoes the five phases of the
cardiac activation and repolarization, and the action potential duration is under 400
ms.

Figure 17: Action Potential plot under normal conditions
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The total activation time, which is the time it takes for the excitation wave to
propagate throughout the ventricles from the apical endocardium to the basal
epicardial wall, is 77 ms. The ventricles completely repolarize at around 368 ms. All
these values are consistent with the literature.26 Figure 18A further captures the
electrical excitation wave at mid propagation from the apex to the base, corresponding
to a time of 45 ms. Figure 18B then shows complete tissue repolarization at time 300
ms. Conversely, Figure19A shows the map of activation times and Figure 19B the
map of repolarization times for ventricles. All these predictions are again consistent
with the literature.26

Figure 18: A) Depolarization at t=45 ms, B) Repolarization at t=300 ms

Figure 19: A) Activation time map, B) Repolarization time map
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ii)

Tissue Mechanics
The Kerckhoff contraction model was used to solve for the active tension,

while the energy function proposed by Holzapfel and Ogden was used to generate the
passive material stress. The passive stress and its Jacobian were developed using the
C++ programming language, and intergrated on Chaste. The material is modeled as
transversly isotropic by zeroing out 4 of the 8 material parameters. The material
parameter values used herein are listed in Table 1, guided by a recent study due to
Baillargeon et al.51, which showed improved prediction of blood ejection fractions.
Table 1: Holzapfel and Ogden material parameters used in this study
A

af

as

afs

b

bf

bs

bfs

0.33

0.25

0

0

7.08

5.34

0

0

For validation, our material
model

was

run

under

the

same

conditions as, and compared against,
the

well-established

transversly

isotropic Pole-Zero material law, whose
material parameters were proposed by
Nash

and

Hunter52.

Both

models

completed simulation of almost 90% of
the cardiac cycle without difficulty,
with our model running faster, reaching
350 ms in 325h 32m and the Pole-Zero
material law reaching 350 ms in 334h
54m. After 90% of the cycle, both
models exhibit instability in the mesh
and diverge, prematurely ending the
simulation.
Figure 20: Ventricular contraction of A)
To highlight the importance of Holzapfel and Ogden model (solid pink)
the fiber orientation in the mechanical against Pole-Zero model (translucent
green)and B) Holzapfel and Ogden
tissue deformation, our transversly model (solid pink) against Mooneyisotropic material model was also Rivlin model (translucent purple)
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compared against the isotropic Mooney-Rivlin material model with material
parameters c1 = 2 and c2 = 6, as proposed by Nash and Panfilov.87 Unlike the
transversly isotropic models, the Mooney-Rivlin model ran till the end of the
simulation reaching 400 ms in 249h 12m.
Figure 20 shows the maximum ventricular contraction resulting from the
models superimposed, with the solid pink representing the Holzapfel and Ogden
model, the translucent green representing the Pole-Zero model (Figure 20A) and the
translucent purple representing the Mooney-Rivlin model (Figure 20B). The models
exhibit similar looking contractions, however the Holzapfel and Ogden model appears
slightly more contracted, which is desirable.
For a proper comparison, a side-by-side map of tissue deformation of the
Holzapfel and Ogden model against the Pole-Zero model, colored by strain
distribution and stress distribution, is shown in Figures 21 and 22, respectively. The
strain and stress maps of the Holzapfel and Ogden model against the Mooney-Rivlin
model are shown in Figures 23 and 24, respectively. The effective deviatoric stress
and the effective deviatoric strain were calculated at each element of the mesh at 50
ms intervals. The deviatoric component of the stress and strain tensors only accounts
for the distortional element of the tensor without the volume change (as tissue is
incompressible); deviatoric stress is calculated as follows:
σ

σ

σ

(3.3)

and the deviatoric strain as:
(3.4)

The effective stress is then calculated as:
σ

σ σ

(3.5)

and the effective strain as:
(3.6)
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Figure 21: Strain distribution maps of the Holzapfel and Ogden model on the left
and the Pole-Zero model on the right at times A) 50 ms, B) 200 ms, C) 300 ms, D)
350 ms
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Figure 22: Stress distribution maps of the Holzapfel and Ogden model on the left
and the Pole-Zero model on the right at times A) 50 ms, B) 100 ms, C) 200 ms, D)
350 ms
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Figure 23: Strain distribution maps of the Holzapfel and Ogden model on the left
and the Mooney-Rivlin model on the right at times A) 50 ms, B) 100 ms, C) 250
ms, D) 350 ms
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Figure 24: Stress distribution maps of the Holzapfel and Ogden model on the left
and the Mooney-Rivlin model on the right at times A) 100 ms, B) 200 ms, C) 300
ms, D) 350 ms
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Looking at the predicted strain maps of the Pole-Zero model compared to the
Holzapfel and Ogden model, small differences appear in the basal area and on the
surface, especially close to the time of 300 ms (repolarization), but both models are
comparable in terms of strain distribution. For the stress distribution maps, however,
the Pole-Zero model clearly exhibits higher stress levels than the Holzapfel and
Ogden model throughout the cycle, which indicates a much stiffer response from the
Pole-Zero model.
As for the Mooney-Rivlin model, the strain appears to be much less
pronounced than the Holzapfel and Ogden model while the stress appears to be much
more pronounced. This indicates that the lack of fiber direction in the cardiac muscles
leads to less tissue deformation and a stiffer response from the model.
To further quantify the mechanical behavior predicted, and decide on which
model is preferable to move forward with, several biomarkers are used, including; the
ventricular volume, the ejection fraction, the left ventricle twist angle between the
apex and the base, the longitudinal strain, and the radial strains. These are analyzed
next.

41

a) Ventricular volume
At each time step, to measure the volume
enclosed by the ventricles (which is irregular), left
ventricle and right ventricle endocardiac nodes are
first separated from the rest of the mesh, and then
from each other. For the ventricular node sets, alpha
shapes are formed where all the nodes are
connected turning the hollow ventricle into a solid
body that is divided into tetrahedrons as shown in
Figure 25. They are used to define the correct
Figure
25:
Delaunay
shape of the irregular cavities of the ventricles and triangulation of the left ventricle
calculate the correct volumes using a ready to calculate volume
developed Matlab code.6
Figure 26 plots the changing volume of the LV and RV through time, when
using the Holzapfel and Ogden model, the Pole-Zero model, and the Mooney-Rivlin
model. The starting volume of the LV and RV are 96.7 cm3 and 96.6 cm3. With the
Holzapfel and Ogden model, the LV reaches a minimum volume of 69.4 cm 3 at time
190 ms and the RV reaches its minimum volume 75.5 cm3 at time 90 ms. As for the
Pole-Zero model, the LV minimum volume reached is 78.7 cm3 at 200 ms and
minimum RV volume of 84.7 cm3 at 90 ms. The Mooney-Rivlin model doesn’t show
much volume difference from the Pole-Zero model with a minimum LV volume of
80.5 cm3 at 200 ms and a RV volume of 85.4 cm3 at 190 ms.
Hence the Holzapfel and Ogden model shows significantly more contraction
than both the Pole-Zero and the Mooney-Rivlin models. Surprisingly, despite the lack
of fiber and sheet directions, the ventricular volume reduction of the Mooney-Rivlin
model is close to that of the Pole-Zero model which indicates that in terms of
ventricular contraction it is not a bad alternative for the Pole-Zero model specially
when accounting for its speed and stability. However, these systolic volumes of the
ventricles do not match those obtained from clinical data, which can reach as low as
24 cm3 and 40 cm3 for the left and right ventricles, respectively92, but they do exhibit
the same patterns of volume change through time.46
6

http://www.mathworks.com/matlabcentral/fileexchange/28851-alpha-shapes/content/alphavol.m
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Figure 26: Volume change through time of A)left and B)right ventricles with the
Holzapfel and Ogden model vs. the Pole-Zero and the Mooney-Rivlin models

b) Ejection Fraction
The ejection fraction (EF) is the percentage of blood ejected from the ventricles
during contraction. It is a very good indicator of how healthy the heart is, by
measuring how well it is pumping blood. It is calculated from the formula93;

(3.7)
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where EDV is the end diastolic volume and ESV is the end systolic volume. The
values of the EFs predicted by the Holzapfel and Ogden, the Pole-Zero, and the
Mooney-Rivlin models are shown in Table 2.
Table 2: Ejection Fraction values for Holzapfel and Ogden vs. Pole-Zero and
Mooney-Rivlin models
Holzapfel and Ogden

Pole-Zero

Mooney-Rivlin

LV

RV

LV

RV

LV

RV

28.2%

21.8%

18.7%

12.2%

16.8%

11.6%

As expected from the volume change curves, the Holzapfel and Ogden model
exhibits a larger EF than the Pole-Zero and Mooney-Rivlin models due to the larger
change in volume. The values are still considerably far from clinical data94, but are
consistent with various computational model results in literature51, and should thus be
sufficient for our purpose of detecting the change in the heart’s performance under
drug influence. In fact, this newly developed model provides a considerable
improvement to the ones on Chaste.

c) Left Ventricle Twist
The helical structure of the fiber distribution in the ventricles induces torsion
in the cardiac muscles during contraction, and plays a crucial role in ventricular blood
filling and ejection.46 As shown in Figure 27, to measure the twist angle in the LV, we
define an axial vector, which extended from a fixed point at the apex to the middle of
the cavity at the base, whose orientation we follow in the initial and the contracted
meshes. A second (radial) vector was extended from the axial vector, standing at the
base, in the middle of the LV cavity, to a chosen point on the LV wall. We also follow
the motion of this radial vector in the initial and contracted meshes. Note that
measuring the angle between the initial and deformed radial vectors is not suitable,
since their orthogonality to the axial vector is not guaranteed, particularly after
contraction. Hence, a third (normal) vector, orthogonal to both the axial and the radial
vectors in each of the meshes, is obtained from the cross product of the axial and
radial vectors. The angle between these normal vectors in the intial and deformed
meshes is thus calculated to indicate the twist angle of the LV.
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Figure 27: A) Undeformed mesh with an axial vector (blue) through the LV and a
radial vector(yellow) connecting it to the LV wall B) Deformed mesh with an
axial vector (red) through the LV and a radial vector(green) connecting it to the
LV wall
Unlike the Mooney-Rivlin model, the resulting twist angle for both transverse
isotropic material models is in very good agreement with the range of experimental
measures in literature.95,96 The changing twist angle over time is plotted in Figure 28.
The Holzapfel and Ogden model predicts a maximum twist angle of 15.3 degrees 80
ms into the simulation while the Pole-Zero model predicts a lower maximum twist
angle of 12 degrees at 90 ms and the Mooney-Rivlin model predicts a maximum twist
angle of 5.2 degrees at 150 ms. The low twisting effect of the Mooney-Rivlin model is
a clear consequence of the lack of fiber and sheet orientation definitions which
indicates their importance in recreating the LV torsion of the contracting heart.
More interesting, is that the trend the Holzapfel and Ogden model predicts for
LV twist angle is more similar to clinical data than the other two models46, which
confirms it is an important improvement of the models in Chaste.
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Figure 28: Left Ventricle rotation angle change over time of the Holzapfel and
Ogden model vs. the Pole-Zero and the Mooney-Rivlin models

d) Longitudinal and Radial Strains
The longitudinal and radial strains
are the main indicators of change in
dimensions. The longitudinal strain is
measured through the septum as shown in
Figure
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to

indicate

longitudinal

shortening during contraction. Two radial
strains are also measured for each
ventricle, one in the lengthening direction
(long) and the other in the shortening
direction (short) as shown in Figure 30.

Figure 29: Longitudinal axis from apex
to base in the undeformed (pink) and
deformed meshes (orange)

The radial strains measured in this
study cannot compare favorably to clinical measurements since the deformation at the
base of the ventricles is actually limited by its attachment to the atria. However, the
measurements are here used to evaluate the change in model dimensions for the
different material models, and under the influence of drugs.
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Figure 30: Radial lines indicating their position in the undeformed mesh (left)
and in the deformed mesh (right)
The plot of the longitudinal strain through time is shown in Figure 31. The
results further support that the Holzapfel and Ogden model is able to produce more
longitudinal shortening, of 12.8%, and exhibit stronger contractile effects than the
Pole-Zero, whose maximum shortening is 11.7% and the Mooney-Rivlin with
maximum shortening of 9.1%.

Figure 31: Longitudinal strain plot for the Holzapfel and Ogden model vs. the
Pole-Zero and the Mooney-Rivlin models
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From the basal view, the ventricles appear to be squeezed in one direction and
stretched in the other, so the radial strain is measured in both directions for each
ventricle. Figure 32 of the LV long side deformation indicates that the anisotropic
models exhibit the same maximum stretch, but different patterns of deformation.
However, for the short side, plotted in Figure 33, the Holzapfel and Ogden model
causes the LV to record larger contraction than the Pole-Zero model. The MooneyRivlin plots indicate that the model does not reach the levels of stretching and
squeezing of the other two models due to the stiffness of the model resulting from the
lack of fiber and sheet directions.

Figure 32: Left Ventricle strain in the long direction for the Holzapfel and Ogden
model vs. the Pole-Zero and Mooney-Rivlin models

Figure 33: Left Ventricle strain in the short direction for the Holzapfel and
Ogden model vs. the Pole-Zero and Mooney-Rivlin models
48

With the regards to the radial strains of the RV, for the long side, all three
models appear to exhibit a similar stretch pattern. However, the Pole-Zero model
seems to be somewhat delayed and the Mooney-Rivlin model gives significantly less
stretching. As for the short side, they again predict similar strain patterns, but the
Holzapfel and Ogden model again records a higher shortening percentage than both
the Pole-Zero and the Mooney-Rivlin models. The percentages of stretching and
shortening are recorded in Table 3.

Figure 34: Right Ventricle strain in the long direction for the Holzapfel and
Ogden model vs. the Pole-Zero and the Mooney-Rivlin models

Figure 35: Right Ventricle strain in the short direction for the Holzapfel and
Ogden model vs. the Pole-Zero and the Mooney-Rivlin models
49

Table 3: Radial stretching and shortening of the Holzapfel and Ogden model and
the Pole-Zero model
Holzapfel and Ogden
LV

Pole-Zero

RV

LV

Mooney-Rivlin
RV

LV

RV

Long

Short

Long

Short

Long

Short

Long

Short

Long

Short

Long

Short

24%

30%

19%

42%

24%

26%

19%

32%

14%

15%

14%

18%

In summary, the results comparing between the two mechanical models
validate the Holzapfel and Ogden model we developed on Chaste for this study, and
in fact the various biomarkers we studied provide sufficient evidence that it gives
superior results in terms of predicting cardiac functionality. The results also validate
the need for fiber orientation definition especially for the modeling of the LV twisting
and the longitudinal shortening.
Therefore, the Holzapfel and Ogden model was selected for the investigation
of the effect of nanodrug influence on cardiac mechanics, whose results are reported
next.
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C) Effects of Sodium channel blockage
The sodium channel activation is responsible for the depolarization of cardiac
myocytes.97 Sodium channel blocks are known to cause activation time delays
resulting from the decrease in conduction velocity through the cardiac tissue.26 This
blockage can be caused by drugs of the type Class I antiarrhythmics, which
specifically target the sodium channels, or even by non-cardiovascular drugs such as
antipsychotics and anticonvulsants.97 The simulation was carried out using the
Holzapfel and Ogden model under the same conditions of the Holzapfel and Ogden
control simulation with an IC50 dose of a sodium channel blocker.

i)

Electrophysiology
Figure 36A compares the average activation time of the simulation under the

influence of a sodium channel blocker with the control and shows an average delay of
about 9 ms. The conduction velocity was also plotted in Figure 36B showing the
sodium channel block causing a decrease in conduction velocity of the action
potential in the ventricles. Figure 37 compares the conduction velocities of the control
and sodium channel blocked simulations. It shows how far along the ventricles the
electrical wave has spread at t = 45ms showing the one under drug influence to be
clearly falling behind. This activation delay and reduced conduction velocity are
consistant with findings in literature.26

Figure 36: The A) activation time and B) conduction velocity of action potential
through the ventricles for control (blue) and for IC50 dose of a sodium channel
blocker (red)
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Figure 37: Electrical wave propagation along the ventricular mesh for A) control and B)
sodium channel blockage
Figure 38 plots the simulated effect of the sodium channel blocker on pseudoECG against the control. Results show a clear prolongation in the QRS complex due
to the decreased rate of depolarization and, even though the blockage does not affect
repolarization, the T-wave experiences a shift forward as a result of the delayed
activation. The alterations in the QT interval match those reported in literature.43

Figure 38: Pseudo-ECG QT interval for control (blue) and for IC50 dose of a
sodium channel blocker (red)
This consequence of the conduction delay during activation on the
repolarization is also clear in the AP plot in Figure 39. The changes in the AP curve
are also consistant with the literature.23,26 It exhibits a decrease in maximum voltage
amplitude and a deflection in the activation-repolarization cycle which results in the
prolongation of the action potential duration. Figure 40 shows a difference in
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repolarization times between the control and the influence of sodium channel block of
about 9 ms, which is the same difference between the activation times confirming that
there is no additional effect on the repolarization by the sodium channel block.

Figure 39: Action potential for control (blue) and for IC50 dose of a sodium
channel blocker (red)
Activation time maps for the
ventricular model in Figure 41 show the
effect of the sodium channel blocker on
the tissue activation time.
gradient

in

Figure

The color

41A shows

the

maximum time for tissue activation under
normal conditions is 77 ms while in Figure
41B

under

sodium

channel

blocker

influence, the same tissue activation time
reaches 100 ms. Figure 42 compares the
repolarization time maps highlighting the

Figure 40: Repolarization time for
influences control (blue) and for IC50 dose of a
sodium channel blocker (red)
simulation. The activation maps produced
slight

delay

in

the

drug

appear to have similar patterns to those found in literature.26
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Figure 41: Activation time maps of the ventricular meshes A) under control
conditions and B) under the influence of sodium channel blocker

Figure 42: Repolarization time maps of the ventricular meshes A) under control
conditions and B) under the influence of sodium channel blocker

It is thus established that simulation results are consistent with experimental
results

21

and computational model results26,43 in literature regarding the effect of

sodium channel blockers on the reduced rate of depolarization and the decreased
action potential conduction velocity.
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ii)

Tissue Deformation
As previously discussed, so far

in literature the effect of drugs has only
been studied on the electrophysiology
of the heart. Studying the mechanical
results will give an answer to how
much these electrical changes affect the
mechanical pumping of the heart.
Figure 43: Ventricular contraction of the
The mechanical results of the control (solid pink) vs. Na+ blocked
coupled simulation under the influence model (translucent green)
of an IC50 dose of a sodium channel nanodrug were compared to the control run under
normal conditions using the same Holzapfel and Ogden material model. Figure 43
shows the ventricular contraction of the two simulations superimposed with the
control as the solid pink mesh and the nanodrug influenced as the translucent green.
They appear to be slightly out of synch, but the data needs to be quantified to
understand the extent of the nanodrug effect on the heart function .
The effective deviatoric strain distribution maps of the nanodrug influenced
model are compared against the control in Figure 44. However, no observable
difference can be noted between the two strain distributions.
The effective deviatoric stress distribution maps are also compared in Figure
45. There does appear to be a slight difference between the 2 distributions. In Figure
45A, stresses seem to rise at the endocardium of the LV at the base in the control
simulation, while they are only just starting to appear in the drug influenced model. In
45B, the stresses rise in the drug influenced model as well, but they appear to be
behind the control. At the end of the simulation, in Figure 45D, the stresses in the
drug influenced model seem to be falling at a lower rate than the control model. So
far, these findings are consistent with what is known about sodium channel blocking
causing a delay in the cardiac cycle.18,26
The mechanical biomarkers are calculated next for the drug influenced model
and compared to the control to quantify the extent of the effect of the sodium channel
blockage on the cardiac function.
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Figure 44: Strain distribution maps of the control on the left and under Na+
channel blocking on the right at times A) 50 ms, B) 150 ms, C) 250 ms, D) 350 ms
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Figure 45: Stress distribution maps of the control on the left and under Na+
channel blocking on the right at times A) 100 ms, B) 150 ms, C) 200 ms, D) 350
ms
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a) Ventricular Volume
The volumes of the left and right ventricles was calculated for the drug
influenced model and plotted against the control. The results are shown in Figure 46.
Both models exhibit similar trends and reach the same minimum ventricular volumes,
but the drug-induced model seems to be lagging behind the control in both the LV and
the RV and this lag not only affected the muscle contraction, but the volume
restoration is falling behind as well. These results indicate that the ventricular
performance has been shifted as a result of the electrophysiology delay.

Figure 46: Volume change through time of A) left and B) right ventricles under
normal conditions and under IC50 dose of Na+ channel blocker
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b) Ejection Fraction
The EFs of the drug induced model were calculated and compared to the
control. The results are recorded in Table 4. The LV EF appears to be unaffected while
the RV, interestingly, seems to have exhibited an increase in the ejection fraction. As
far as we know, these results are new and there are no reports to compare them to.
Table 4: Ejection Fraction values for the control vs. the Na+ channel blocked
model
Control

Sodium Channel Blocker

LV

RV

LV

RV

28.2%

21.8%

28.2%

22.5%

c) Left Ventricle Twist
The twisting motion of the LV is crucial in the cardiac functionality and risky
if compromised. Figure 47 plots the LV twist angle of the drug induced model against
the control. As expected, the rate of angle twist decreases as a consequence of the
sodium channel block delay. This checks out with the literature.19 However, the
maximum twist angle reached by the LV is higher in the drug induced model reaching
almost 17 degrees. This result is also new and unpredicted and the cause of which
would make for an interesting study.

Figure 47: Left Ventricle rotation angle change over time under normal
conditions and under IC50 dose of Na+ channel blocker
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d) Longitudinal and Radial Strains
As shown in Figure 48, the longitudinal strain measures of the drug influenced
model exhibit similar trends to the control, but at a lower rate. The same longitudinal
axis shortening during contraction is achieved by both models, but, as predicted by
the electrophysiology, the drug influenced model was delayed.18,19

Figure 48: Longitudinal strain under normal conditions and under IC50 dose of
Na+ channel blocker
The same delay is experienced in the radial strains as well. However, in both
ventricle, except for the stretching in the RV long direction, which is similar to the
control, there appear to be a higher percentage of stretching and shortening in the drug
induced model. The exact percentages are recorded in Table 5 and the radial strain
plots of the LV and RV are shown in Figures 49, 50, 51 and 52. This increased
mechanical performance is an unexpected finding and more research is needed to
understand its cause and subsequent effect.
Table 5: Radial stretching and shortening of the control and Na+ channel
blocked model
Control
LV

Sodium Channel Block
RV

LV

RV

Long

Short

Long

Short

Long

Short

Long

Short

24%,

30%

19%

42%

25.8%

32.2%

19%

45.8%
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Figure 49: Left Ventricle strain in the long direction for control and Na+channel
blocked model

Figure 50: Left Ventricle strain in the short direction for control and Na+channel
blocked model
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Figure 51: Right Ventricle strain in the long direction for control and
Na+channel blocked model

Figure 52: Right Ventricle strain in the short direction for control and
Na+channel blocked model
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D) Simulation of the effects of Potassium channel blockage
In simulating the effect of
potassium channel blockage on the
function of the heart, the effect of ultrasmall gold nanoparticles of 1.4 nm
diameter (Au1.4MS) that are frequently
used as drug carriers were chosen as an
example drug to investigate. With an
IC50 value of 48 μM17 the potassium
channel

blockage

of

100

μM

concentration of the drug, using the
formula in equation (2.1) causes a
blockage of 68%. A simulation was

Figure 53: Average repolarization time
carried out under the same control of the ventricles for control (blue) and
for Au1.4MS influence (red)
conditions with 100 μM concentration
of Au1.4MS as the potassium channel blocker.

i)

Electrophysiology
Figure 53 shows the difference in repolarization time of about 30 ms between

the control simulation and AuNP-influenced simulation. A side by side comparison of
the 2 simulations at time 300 ms during repolarisation shows the control simulation
ahead of the drug influenced once is shown in Figure 54. These results are a good
match to reports in literature.26

Figure 54: Repolarization of the ventricular mesh tissue of A) control and B)
AuNP-influenced simulations
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The pseudo-ECG of the potassium channel blocking simulation in Figure 55
does not show difference from the control during the depolarization in the QRS
complex. The change can be observed in the increase in the QT interval and the lower
T-wave amplitude due to decreased dispersion during repolarization similar to
changes reported in literature.44,98

Figure 55: Pseudo-ECG QT interval for control (blue) and for Au1.4MS
influence (red)
In Figure 56, the AP plot comparing the results of the control and potassium
channel blocker, shows the activation in both cases as almost exactly the same. The
deviation can be seen during the repolarization phase of the action potential as
potassium channel blockage leads to delayed repolarization and increase in action
potential duration. The results appear to be consistent with reports in literature.44,98
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Figure 56: Action potential for control (blue) and for Au1.4MS influence (red)
Repolarization time maps for the ventricular model in Figure 57 show the
effect of the potassium channel blocker on the tissue repolarization time. The color
gradient in Figure 57A shows the maximum time for tissue repolarization under
normal conditions is 391 ms while in Figure 57B under nanodrug influence, the same
tissue repolarization time reaches 397 ms. The simulation results are as such
consistent with findings in literature regarding the effect of potassium channel
blockers on the action potential duration prolongation due to the decreased rate of
ventricular tissue repolarization.26

Figure 57: Repolarization time maps of the ventricular mesh under A) normal
conditions and B) the influence of potassium channel blocker
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ii)

Tissue Deformation
Figure 58 shows the ventricular

mesh at the end of the simulation near the
end of the cardiac cycle in the control and
the AuNP-influenced models. From the
electrophysiological

results,

potassium

channel blockers are known to cause
repolarization

delay.44

Therefore,

differences between the behavior of the
control and the AuNP-induced model
should begin to appear near the end of
ventricular Figure 58: Ventricular contraction
of the control (solid pink) vs. K+
relaxation. There does not appears to be channel blocked model (translucent
any visual difference between them the 2 green)
the

simulation

during

models in Figure 58.
The effective deviatoric strain and the effective deviatoric stress maps of the
AuNP-induced model are shown in Figures 59 and 60, respectively, in comparison
with the control model. The stress and strain color distributions do not show any
difference between the two models either. According to electrophysiological
findings,44 the results are expected to remain identical for about 250 ms after which
change is expected, but so far doesn’t appear. The other biomarkers are needed to
shed more light on the AuNP-influenced mechanical behavior of the heart.
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Figure 59: Strain distribution maps of the control on the left and under K+
channel blocking on the right at times A) 50 ms, B) 150 ms, C) 250 ms, D) 350 ms
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Figure 60: Stress distribution maps of the control on the left and under K+
channel blocking on the right at times A) 50 ms, B) 150 ms, C) 250 ms, D) 350 ms
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a) Ventricular Volume
The left and right ventricular volumes were calculated at each time step and
compared to the control volume measurements. The plots are shown in Figure 61. The
volume change in the LV is exactly the same in both the control and the AuNPinduced model. As for the RV volume, there appears to be an extremely slight change
between the 2 models at the very last simulation time step. Other than that, the
volume change is identical. The ventricular volume restoration was expected to slow
down as the repolarization in the AP slows down26, but that effect did not appear.

Figure 61: Volume change through time of A) left and B) right ventricles under
normal conditions and under K+ channel blocker
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b) Ejection Fraction
The EF is not a suitable biomarker for potassium channel blockage as it does
not affect the activation26 and therefore does not affect systole. Since there is no
volume change between the 2 models, the EF of the AuNP-induced model is identical
to the control. The values are shown in Table 6.
Table 6: Ejection Fraction values for the control vs. the K+ channel blocked
model
Control

Potassium Channel Blocker

LV

RV

LV

RV

28.2%

21.8%

28.2%

21.8%

c) Left Ventricle Twist
Again, the twist angles of the drug-induced model are the same as the control
which is as expected since the twist occurs near the beginning of the cycle where the
potassium channel block shows no effect on the electrophysiology.26,44 However,
between the times 300 ms and 350 ms, a small change starts to appear between the 2
models, as seen in Figure 62.

Figure 62: Left Ventricle rotation angle change over time under normal
conditions and under K+ channel blocker
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d) Longitudinal and Radial Strains
Figure 63 plots the longitudinal strain of the drug induced model against the
control. The LV and RV radial strains are plotted as well in Figures 64, 65, 66 and 67.
The strains shows the same behavior of the other biomarkers where the results are
identical to the control. Again this is unexpected. More visible differences were
expected to appear near the end of the cycle such as a slower rate of recovery.

Figure 63: Longitudinal strain under normal conditions and under K+ channel
blocker

Figure 64: Left Ventricle strain in the long direction for control and K+ channel
blocked model
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Figure 65: Left Ventricle strain in the short direction for control and K+ channel
blocked model

Figure 66: Right Ventricle strain in the long direction for control and K+ channel
blocked model
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Figure 67: Right Ventricle strain in the short direction for control and K+
channel blocked model
Potassium channel blockers are known to affect the final (repolarization)
phase of the cardiac cycle. So its behavior being identical to the control is expected in
the first half or two thirds of the cycle. As expected, there was no change in the EF or
the maximum LV twist angle as these two biomarkers are systole quantifying
biomarkers. The differences were expected to be seen in the restoration curves of the
volume and strain plots. The differences were expected to appear at around the same
time they appear in the electrophysiology which is at 250 ms. That did not happen and
only very slight changes appeared in some cases at the very end of the simulation. The
most likely reason it is late in showing compared to electrophysiology is that the
mechanical deformation is slow to respond to electrical excitation. The fact that only
350 ms of the cycle are available in this study is a shortcoming since the effect may
appear in the last 50 ms and pass over into the next cycle.
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E) Simulation of the effects of Calcium channel blockage
Calcium dynamics form the link between electrical activation and mechanical
contraction63 since the generation of the active tension depends on intracellular
calcium concentration as previously mentioned.60 The L-type calcium channel is a
pathway found in all cardiac cell membranes and is the principle pathway of calcium
into the cell.2 The blockage of L-type calcium channel has been known to cause
reduction in the T-wave amplitude and shortening in the QT interval caused by the
reduction of the action potential duration.42 Drugs that cause calcium channel
blocking have many clinical applications such as reducing blood pressure and altering
heart rate.42 A simulation was carried out under the influence of the IC50 dose of a
calcium channel blocker using the same control conditions and the results are shown
below.

i)

Electrophysiology
Figure

difference

68

shows

in

the

average

repolarization times between the
control and under the influence
of a calcium channel blocker. The
plot shows the simulation with
the

calcium

channel

blocker

repolarizing about 50 ms ahead
of the control simulation.
Figure 69 shows a side by
side comparison of the electrical

Figure 68: Average repolarization time of the
potential of the two simulations at ventricles for control (blue) and for IC50 dose
time 300 ms during repolarization. of a calcium channel blocker (red)
The images show the repolarization of the drug-influenced simulation to be clearly
ahead of the control. These results are consistent with findings in literature.42
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Figure 69: Repolarization of the ventricular mesh tissue at time 300 ms of A)
control and B) calcium channel blockage
The effect of blocking L-type calcium channel on the pseudo-ECG is plotted
against the control in Figure 70. The drug barely affects the QRS complex with only a
very small decrease its amplitude. The T-wave, however, experiences a significant
shift backwards leading to shortening of the QT interval. There is also a slight
decrease in the T-wave amplitude. These alterations in the QT interval match those
reported in literature.42

Figure 70: Pseudo-ECG QT interval for control (blue) and for IC50 dose of a
calcium channel blocker (red)
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The action potential plot comparing the control simulation with the simulation
under the influence of a calcium channel blocker is shown in Figure 71. The
activation of both appear to be almost the same except for a slight reduction in
amplitude of the drug-influenced simulation. A more significant difference appears in
the plateau and repolarization phases. There is a reduction in the voltage at the plateau
phase and early repolarization for the drug-influenced simulation which agree with
reports in literature.99

Figure 71: Action potential for control (blue) and for IC50 dose of a calcium
channel blocker (red)
Repolarization time maps for the ventricular model shown in Figure 72 show
the effect of L-type calcium channel blocking on the tissue repolarization time. The
color gradient in Figure 72A shows the maximum time for tissue repolarization under
normal conditions is 368 ms while in Figure 72B under drug influence, the same
tissue repolarization time reaches only 318 ms.
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Figure 72: Repolarization time maps of the ventricular mesh under A) normal
conditions and B) the influence of calcium channel blocker
All the electrophysiological simulation results are as such consistent with
findings in literature regarding the effect of L-type calcium channel blockers on the
action potential duration shortening due to early repolarization.42,99
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iii)

Tissue Deformation
The electrophysiological simulations

indicate that the calcium channel blocked
model should repolarize and reach the end of
the cardiac cycle 50 ms before the control.
This means that the nanodrug induced model
should be relaxing much faster than the
control. That, however, does not seem to be
the case in Figure 73 which shows the
Figure 73: Ventricular models of the
control (solid pink) vs. Ca2+ channel
control and the calcium channel blocked blocked model (translucent green)
superimposed ventricular models of both the

model. There doesn’t appear to be any visible difference between the relaxation of the
two models.
The comparison between the effective deviatoric strain and the effective
deviatoric stress maps of the L-type calcium channel blocked model and the control
are shown in Figures 74 and 75, respectively. The stress and strain color distributions
do not show differences between the two models either. According to
electrophysiological findings,42 differences are expected to appear in the results, at
least during diastole, but so far there are none. Further mechanical biomarkers are
needed to shed light on the calcium channel blocking nanodrugs’ influence on
mechanical behavior of the heart.
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Figure 74: Strain distribution maps of the control on the left and under Ca2+
channel blocking on the right at times A) 50 ms, B) 150 ms, C) 250 ms, D) 350 ms
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Figure 75: Stress distribution maps of the control on the left and under Ca2+
channel blocking on the right at times A) 50 ms, B) 150 ms, C) 250 ms, D) 350 ms
80

a) Ventricular Volume
The left and right ventricular volumes were calculated at each time step and
compared to the control volume measurements with the results plotted in Figure 76.
The volume change in the LV and the RV are similar in both the control and the
nanodrug-induced model. Reports in literature42,99 and the electrophysiological results
of the simulation support the expectation that the ventricular volume for the calcium
channel blocked model was to be restored faster than the control. The direct link
between the calcium concentration and the ventricular mechanical response60 also
supports the claim that the blocking the calcium channel would have a significant
effect on the volume change. However, neither of these expectations occurred in the
volume change of both models.

Figure 76: Volume change through time of A) left and B) right ventricles under
normal conditions and under Ca2+ channel blocker
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b) Ejection Fraction
Since calcium channel blocking with an IC50 dose did not affect ventricular
contraction in our simulation of a single cardiac cycle,60 no difference was predicted
between the control and the nanodrug-induced EFs. There appears to be a very slight
increase in the EF of the RV in the nanodrug-influenced model; however, we deem it
too small to have significance in the simulated cycle. The values are given in Table 7.
Table 7: Ejection Fraction values for the control vs. the Ca2+ channel blocked
model
Control

Calcium Channel Blocker

LV

RV

LV

RV

28.2%

21.8%

28.2%

21.9%

c) Left Ventricle Twist
As shown in Figure 77, the calcium channel block does not appear to have any
significant effect on the LV twist angle value. Neither was the LV twisting restored
faster in the model under the nanodrug influence, nor was the twisting strength
affected by the change in the calcium concentration.

Figure 77: Left Ventricle rotation angle change over time under normal
conditions and under Ca2+ channel blocker
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d) Longitudinal and Radial Strains
The longitudinal strain of the calcium channel blocked model against the
control is plotted in Figure 78. The LV and RV radial strains are plotted as well in
Figures 79, 80, 81 and 82. The behavior of the strains is similar to the behavior of the
other biomarkers with the results similar to the control. Contrary to the reported
results, visible differences were expected to appear during the cycle due to the change
in the calcium concentration and the strain values were expected to be restored
faster.42, 60

Figure 78: Longitudinal strain under normal conditions and under Ca2+ channel
blocker

Figure 79: Left Ventricle strain in the long direction for control and Ca2+ channel
blocked model
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Figure 80: Left Ventricle strain in the short direction for control and Ca2+
channel blocked model

Figure 81: Right Ventricle strain in the long direction for control and Ca2+
channel blocked model
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Figure 82: Right Ventricle strain in the short direction for control and Ca2+
channel blocked model
L-type calcium channel blockers are known in literature to reduce the QTinterval and the action potential duration due to early repolarization.42,99 The calcium
dynamics are also known to be the direct link between the electrophysiology and the
mechanical contractile behavior of the cardiac tissue.60 Therefore, our expectation by
applying an IC50 value of a calcium channel blocker was to predict a disturbance in
the mechanics of the whole cycle compared to the control. That, however, was not the
case as seen in the results of the tissue deformation biomarkers. The results were all
similar to the control. The IC50 value of a calcium channel blocker was enough to
cause electrophysiological changes; however, it could be that the mechanics is not
sensitive enough to detect these changes, so that a greater channel inhibition needs to
be tested for mechanical disturbances to appear. It is also thought that one cardiac
cycle is not sufficient to affect the deformation abnormalities, so that modeling more
than one cycle could be needed to access the effect of calcium channel blockage on
the mechanical behavior. Thus, our predictions on calcium blockage will need to be
elaborated in future work.

85

4) Conclusion
The objectives of this study were to model accurately a single ventricular
contraction-relaxation cycle and monitor the effect induced by nanodrugs on LV and
RV electro-mechano-physiology. The objectives of this study were thus achieved. The
nanodrugs causing sodium channel blockage were found to produce the expected
delays, and predicted additionally other effects on LV twisting and ventricular strain.
The nanodrugs causing potassium and calcium channel blockage showed that the
mechanics does not respond as quickly to the electrophysiology as does the
electrophysiology to ionic changes. Nonetheless, it is possible for small deviations
from the normal to accumulate over multiple cardiac cycles, and lead to adverse
consequences on cardiac health in the long term. As such, multi-cycle investigations
of K+ and Ca2+ effects on cardiac electro-mechanics are recommended for future
work.
Chaste was chosen as the software to build our model on, as it offers an open
source multiphysics framework to build the coupled (drug-electro-mechanophysiological) system.
Two material laws for modeling passive material stress were already in place
on Chaste; however, new reports in literature suggested that the orthotropic Holzapfel
and Ogden material law was better suited than the isotropic (Mooney-Rivlin) or the
transversely isotropic hyperelastic model (Pole-Zero) available in Chaste. The
Holzapfel and Odgen material law was thus developed for implicit finite element
implementation, incorporated on Chaste, and used to solve the coupled multiphysics
model. To check the validity of the material law, it was compared to the transverse
isotropic Pole-Zero law. To validate the importance of fiber orientation definition in
mechanical modeling, the Holzapfel and Odgen model was also compared to the
isotropic Mooney-Rivlin model.
All three models solved 90% of the target cardiac cycle, before meeting mesh
instabilities. The results showed not only that the Holzapfel and Ogden model was
less stiff than both the Pole-Zero model and the Mooney-Rivlin model, but that even
when using the material law as transversely isotropic (confining it to four parameters
only, and not using its full orthotropic capability), it showed better mechanical
performance in terms of ventricular volume reduction, ejection fraction, left
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ventricular twisting, and longitudinal shortening. These are all key mechanical
biomarkers where the Holzapfel and Ogden model outperforms its competitors preprogrammed on Chaste.
Encouraged by the mechanical predictions of the Holzapfel and Ogden model,
three nanodrug effects were then investigated in the coupled multiphysics framework,
in the form of the IC50 value of a sodium channel blocker (such as silver
nanoparticles), a 100 μM dose of ultrasmall gold nanoparticle drug carriers and the
IC50 value of a calcium channel blocker (such as ZnO nanoparticles). The
electrophysiological predictions were found to be consistent with the information
published in literature. For the mechanics, the delay in the electrical activation caused
by the sodium channel blocker was translated into a delay in all the mechanical
biomarkers of the ventricles, as expected. Further interesting predictions were made,
which require further study; they are the increased LV twist angle and the increased
stretching and shortening of the ventricles in the radial directions as a result of sodium
channel blockage.
For the potassium channel blocking effect the results turned out, predictably,
the same as for the control, since the electrical activation and hence the contraction
are not affected by potassium channel blockage. Unfortunately, modeling only 90% of
the cycle was thus not enough to reveal how ventricular relaxation would be affected,
since the effects were only starting to appear as the simulation terminated.
As for the calcium channel blocker, the IC50 value was enough to cause
electrophysiological changes from the control, however, these changes were not
translated to the tissue mechanics. It might be that the mechanics are not sensitive
enough to detect these changes, so a larger channel inhibition needs to be tested for
mechanical disturbances to appear, or one cardiac cycle is just not sufficient to affect
the deformation abnormalities and modeling more cycles will be required to access
the effect of calcium channel blockage on the mechanical behavior.
For the future work of this study more information is needed to understand the
unexpected mechanical behavior of the sodium channel blocked model and the
calcium channel blocked model and to acquire more conclusive results about the
potassium channel blocked model. The first step would be to fix the mesh stability of
the models on Chaste, e.g. using compressible models with a large bulk modulus to
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mimic incompressible behavior less restrictively, to enable the completion of the first
cardiac cycle and to open the possibility of modeling more than one cycle.
Another issue that might be affecting the sensitivity of the model to the
nanodrug effects is that the mechanical response is not fed back to the
electrophysiology. This feedback effect was not accounted for in this work since, on
Chaste, it is very computationally expensive to apply on big meshes such as the one
used here. Nonetheless, this two-way coupling is crucial and needs to be tested since
even small changes in the mechanics could amplify electrical changes which in turn
would amplify changes in the mechanics.
Improvement to EF can be made in the LV and RV simulation if we revise the
boundary conditions. Fixing the apex and leaving the base free is the opposite of the
natural order of things. At the moment these boundary conditions are the most stable.
It is a good compromise since the ventricles are still able to contract and twist,
however, the lack of atria in the model leave the base completely free to spread as the
muscles contract downwards as shown in Figure 83 and as evidenced from the radial
strain results.

Figure 83: Longitudinal slice through the ventricles A) in diastole and B) in
systole
The trick lies in finding boundary conditions that simulate the effect of atrial
attachment to the base without increasing its stiffness. Sliding wall boundary
conditions are currently being tested where the boundary nodes can be fixed in one or
two directions and left to slide freely in the third, but it is facing graver stability
issues. Since, Dirichlet boundary conditions are not the best option for biological soft
tissue, Robin-like boundary conditions, where a spring-like and viscous effect is
88

applied at the desired surface, are also being investigated. Improving the boundary
conditions is expected to primarily achieve significant improvements to the
mechanical performance of the model in terms of ventricular volume reduction and
ejection fraction, and further contribute to model stability to simulate multiple cardiac
cycles.
Another problem that might be compromising the stability, is the selected
mechanics solver time step. The problem was set to solve the mechanics every 10 ms
as solving the mechanics problem for such a large mesh is computationally very
expensive. The idea provided a significant speed-up, but seemed to experience
difficulty near the end of the simulation, which eventually crashed. If the muscles are
relaxing too quickly during repolarization, the mechanical changes in each time step
might be too great for such a spaced out time-stepping scheme.
From the perspective of drugs, combining nanodrug effects is an important
phenomenon to look into since some nanocomposites could contain more than one ion
channel inhibiting component or even a single nanoparticle such as CuO mentioned in
the introduction could be associated with both sodium and potassium channel
blocking.
With the quick advances taking place in the field of nanomedicine and the
excitement of the potential it holds, the side effects need to be considered and
monitored. Computational models are an inexpensive way of doing that. Therefore,
the more the data and information that can be obtained from the drug testing models,
the more accurate and reliable they can become and the more widely used they will
be. This could significantly reduce the need for animal testing and reduce the time and
cost it takes to release a much-needed cure for a disease.
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